Acceleron Pharma Inc  

(Public, NASDAQ:XLRN)   Watch this stock  
Find more results for XLRN
35.92
-0.08 (-0.22%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 35.39 - 36.10
52 week 23.07 - 40.35
Open 36.10
Vol / Avg. 1.10M/291,129.00
Mkt cap 1.58B
P/E     -
Div/yield     -
EPS -2.58
Shares 45.24M
Beta 1.59
Inst. own 91%
Feb 27, 2018
Q4 2017 Acceleron Pharma Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Dec 11, 2017
Acceleron Pharma Inc to Review Data Presented at 59th ASH - Webcast
Nov 7, 2017
Q3 2017 Acceleron Pharma Inc Earnings Release
Nov 7, 2017
Q3 2017 Acceleron Pharma Inc Earnings Call - Webcast
Sep 19, 2017
Acceleron Pharma Inc to Host Research and Development Day - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -844.43% -205.30%
Operating margin -848.64% -238.04%
EBITD margin - -232.00%
Return on average assets -34.62% -28.94%
Return on average equity -37.32% -34.05%
Employees 121 -
CDP Score - -

Address

128 Sidney St
CAMBRIDGE, MA 02139-4239
United States - Map
+1-617-6499200 (Phone)
+1-617-6499988 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Officers and directors

Francois E. Nader M.D. Independent Chairman of the Board
Age: 60
Bio & Compensation  - Reuters
Habib J. Dable President, Chief Executive Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kevin F. McLaughlin Chief Financial Officer, Senior Vice President, Treasurer
Age: 60
Bio & Compensation  - Reuters
Matthew L. Sherman M.D. Executive Vice President and Chief Medical Officer
Age: 61
Bio & Compensation  - Reuters
Ravindra Kumar Ph.D Senior Vice President, Chief Scientific Officer
Age: 57
Bio & Compensation  - Reuters
John D. Quisel J.D., Ph.D. Senior Vice President, Business Development, General Counsel and Secretary
Age: 45
Bio & Compensation  - Reuters
Karen L. Smith M.D. Ph.D. Director
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 59
Bio & Compensation  - Reuters
George S. Golumbeski Ph.D. Independent Director
Age: 59
Bio & Compensation  - Reuters
Terrence C. Kearney Independent Director
Age: 62
Bio & Compensation  - Reuters